Biocryst Pharmaceuticals (BCRX): Politician trade (House)

$1,001–$15,000
Reported range · official band, not an exact amount: 56 days
Disclosure lag

Traded: Jul 10, 2026
Disclosed: Sep 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

May 19, 2026Federal contract · $151K obligatedDepartment of Veterans Affairs awarded BIOCRYST PHARMACEUTICALS INC: $151K obligated to date
May 21, 2026Federal contract · $30K obligatedDepartment of Veterans Affairs awarded BIOCRYST PHARMACEUTICALS INC: $30K obligated to date
Jun 11, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 11, 2026, at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Company’s stockholders approved, by the affirmative vote of a majority of the shares of the Company’s common stock represented in person or by proxy at the Annual Meeting and voting on the proposal, a proposal to amend and restate the BioCryst…”
Jun 25, 2026Company filing · Form 8-K · Restructuring, Reg FDAnnounced job cuts, closures or a restructuring, and shared information with investors“On June 25, 2026, the Board of Directors of BioCryst Pharmaceuticals, Inc. (the “Company”) approved a plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”).”
Jun 25, 2026Company filing · Form 8-K · RestructuringAnnounced job cuts, closures or a restructuring“On June 29, 2026, the Company announced its plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”) as part of the Company’s ongoing strategic evolution to strengthen its rare disease pipeline.”
Jul 10, 2026 · this disclosureCongressDisclosed purchase of BCRX — reported range $1,001 - $15,000

What came next

Aug 5, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Biocryst Pharmaceuticals

For Biocryst Pharmaceuticals, OQRO holds 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BCRX page.

Other recent filings by Rep. Gilbert Cisneros (CA31)

The full history of Rep. Gilbert Cisneros (CA31) is on the profile page.

Other disclosures at Biocryst Pharmaceuticals

Everything OQRO holds on this company is on its BCRX page.

Biocryst Pharmaceuticals (BCRX)Rep. Gilbert Cisneros (CA31) disclosed a purchase $1K–$15K